Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs)

被引：0

作者：

Wu, Linda

Ozbek, Umut

van Hyfte, Grace

Reincke, Marlene

Gampa, Anuhya

Abugabal, Yehia I.

Nishida, Naoshi

Wietharn, Brooke

Amara, Suneetha

Balcar, Lorenz

Pinter, Matthias

Vogel, Arndt

Weinmann, Arndt

Saeed, Anwaar

Rimassa, Lorenza

Naqash, Abdul Rafeh

Muzaffar, Mahvish

Huang, Yi-Hsiang

Pinato, David James

Ang, Celina

机构：

[1] Mt Sinai Hosp, Tisch Canc Inst, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Univ Freiburg, Fac Med, Med Ctr, Freiburg, Germany

[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Kindai Univ, Osaka, Japan

[8] Univ Kansas, Sch Med, Kansas City, KS USA

[9] East Carolina Univ, Greenville, NC 27858 USA

[10] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, Vienna, Austria

[11] Med Univ Vienna, Vienna, Austria

[12] Hannover Med Sch, Hannover, Germany

[13] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mainz, Germany

[14] Kansas Univ, Canc Ctr, Kansas City, KS USA

[15] Humanitas Univ, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy

[16] NCI, Dev Therapeut Clin, Early Clin Trials Dev Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

[17] East Carolina Univ, Vidant Canc Ctr, Greenville, NC 27858 USA

[18] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Inst Clin Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[19] Imperial Coll, Dept Surg & Canc, London, England

[20] Mt Sinai Hosp, Tisch Canc Inst, Dept Med, Div Hematol Oncol, New York, NY 10029 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.399

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

399

引用

页数：3

共 50 条

[1] Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
Cowzer, D.
Capanu, M.
Keane, F.
Khalil, D.
Shia, J.
Do, R.
Chou, J.
Walch, H.
El Dika, I.
Yaqubie, A.
Solit, D.
Berger, M.
O'Reilly, E.
Harding, J.
Abou-Alfa, G.
[J]. ANNALS OF ONCOLOGY, 2023, 34 : S109 - S109
[2] Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
Wu, Y. Linda
van Hyfte, Grace
Ozbek, Umut
Reincke, Marlene
Gampa, Anuhya
Mohamed, Yehia I.
Nishida, Naoshi
Wietharn, Brooke
Amara, Suneetha
Lee, Pei-Chang
Scheiner, Bernhard
Balcar, Lorenz
Pinter, Matthias
Vogel, Arndt
Weinmann, Arndt
Saeed, Anwaar
Pillai, Anjana
Rimassa, Lorenza
Naqash, Abdul Rafeh
Muzaffar, Mahvish
Huang, Yi-Hsiang
Kaseb, Ahmed O.
Kudo, Masatoshi
Pinato, David J.
Ang, Celina
[J]. FRONTIERS IN ONCOLOGY, 2023, 13
[3] The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients
Wei, C.
Yi, C.
Qing, H.
Shaohua, Y.
Weifeng, W.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S695 - S695
[4] Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors
Chen, Krista Y.
Popovic, Aleksandra
Hsiehchen, David
Baretti, Marina
Griffith, Paige
Bista, Ranjan
Baghdadi, Azarakhsh
Kamel, Ihab R.
Simon, Sanford M.
Migler, Rachael D.
Yarchoan, Mark
[J]. CANCERS, 2022, 14 (21)
[5] Regorafenib joins immune checkpoint inhibitors (ICIs) for previously ICIs plus TKIs failed advanced hepatocellular carcinoma (HCC) patients: A retrospective study.
Zhao, Jie
Yang, Chao
Han, Guoyong
Zhang, Long
Jiang, Chuanwei
Ding, Wenzhou
Hu, Yuanchang
Ni, Ming
Wu, Chen
Xia, Yongxiang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16118 - E16118
[6] PRE- AND POST-TRANSPLANT OUTCOMES OF PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH AND WITHOUT IMMUNE CHECKPOINT INHIBITORS (ICIS) PRIOR TO LIVER TRANSPLANT
Dave, Shravan
Yang, Kun
Schnickel, Gabriel T.
Kono, Yuko
Zhang, Xinlian
Tu, Xin M.
Ajmera, Veeral H.
[J]. HEPATOLOGY, 2021, 74 : 899A - 900A
[7] Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
Reyes, Kevin R.
Zhang, Li
Zhu, Xiaolin
Jindal, Tanya
Deshmukh, Prianka
de Kouchkovsky, Ivan
Kumar, Vipul
Maldonado, Edward
Kwon, Daniel H.
Chan, Emily
Porten, Sima P.
Borno, Hala
Bose, Rohit
Desai, Arpita
Aggarwal, Rahul Raj
Small, Eric Jay
Fong, Lawrence
Chou, Jonathan
Friedlander, Terence W.
Koshkin, Vadim S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC)
Paul, Samuel
Min, Eric
Benson, Katherine K.
Xu, Menglin
Noonan, Anne M.
Mittra, Arjun
Malalur, Pannaga G.
Roychowdhury, Sameek
Jin, Ning
Hays, John L.
Elkhatib, Rifat T.
Rahman, Shafia
Miller, Eric David
Pardo, Dayssy Alexandra Diaz
Manne, Ashish
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[9] Association of race with clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
Choi, Yujin
Yildirim, Ahmet
Wei, Mengting
Liu, Yuan
Goswamy, Rohit Vivek
Brown, Jacqueline T.
Nazha, Bassel
Martini, Dylan J.
Hartman, Caitlin
McClintock, Greta Russler
Zhuang, Tony
Kissick, Haydn
Harris, Wayne B.
Carthon, Bradley Curtis
Kucuk, Omer
Master, Viraj A.
Bilen, Mehmet Asim
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[10] Impact of metformin on clinical outcomes in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.
Khalil, Lana
Kang, Sandra
McCook-Veal, Ashley
Draper, Amber
Diab, Maria
Shaib, Walid Labib
Alese, Olatunji B.
El-Rayes, Bassel F.
Akce, Mehmet
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →